{
    "nctId": "NCT05963984",
    "briefTitle": "A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants",
    "officialTitle": "An Open-label, Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant With or Without Samuraciclib in Participants With Metastatic or Locally Advanced Hormone Receptor (HR) Positive and Human Epidermal Growth Factor Receptor (HER)2-Negative Breast Cancer (BC)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Clinical Benefit Response (CBR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed diagnosis of ER-positive, HER2-negative locally advanced or metastatic breast cancer.\n* Documented objective disease progression while on or within 6 months after the end of the most recent therapy.\n* Received prior AI in combination with a CDK4/6i as the last therapy\n* Known TP53 mutation status.\n* Participants must have measurable disease or bone only disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Pre/peri-menopausal participants must have commenced treatment with a luteinizing hormone-releasing hormone (LHRH) agonist at least 4 weeks prior to first dose of study intervention.\n* Eastern Cooperative Oncology Group (ECOG) performance status \u22641 with no deterioration over the past 2 weeks.\n* Expected life expectancy of \\>12 weeks in the judgement of the treating investigator.\n\nExclusion Criteria:\n\n* Inflammatory breast cancer.\n* Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.\n* More than 1 line of endocrine treatment for locally advanced or metastatic disease treatment.\n* Inadequate hepatic, renal, and bone marrow function.\n* Clinically significant cardiovascular disease.\n* Any current or prior central nervous system metastases, carcinomatous meningitis, or leptomeningeal disease.\n* Pregnant or breastfeeding women.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}